Myxoid liposarcoma: it's a hippo's world

Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated pr...

Full description

Saved in:
Bibliographic Details
Published in:EMBO molecular medicine 2019-05, Vol.11 (5), p.1-n/a
Main Authors: Regina, Carla, Hettmer, Simone
Format: Article
Language:English
Subjects:
Adapter proteins
Apoptosis
Cancer therapies
Cell cycle
Chemotherapy
DNA damage
EMBO03
Gene expression
Growth factors
Humans
Kinases
Leukemia
Liposarcoma
Liposarcoma, Myxoid - enzymology
Liposarcoma, Myxoid - pathology
Models, Biological
Mutation
News & Views
Protein-Serine-Threonine Kinases - metabolism
RNA-mediated interference
Sarcoma
Senescence
Signal Transduction
Stem cells
Studies
Transcription
Transcription factors
Tumors
Views
Yes-associated protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fused in sarcoma: DNA damage‐inducible transcript 3 protein (FUS:DDIT3) is a chimeric fusion oncoprotein present in 90% of human myxoid liposarcomas (MLS). The study by Trautmann et al in this issue of EMBO Molecular Medicine utilizes a drop‐out RNAi screen to establish hyperactive Yes‐associated protein 1 (YAP1), a major downstream nuclear effector of the Hippo signaling pathway, as a selectively essential transcript promoting viability and growth of MLS. These observations add to a growing body of evidence underscoring the importance of dysregulation of Hippo signaling in soft‐tissue sarcomas expressing fusion oncoproteins and identify a novel target for therapeutic intervention in MLS. Comprehensive molecular characterization pipelines are needed to screen patients with advanced soft‐tissue sarcomas for the presence of druggable alterations, including but not limited to nuclear YAP1 expression in MLS, to facilitate treatment decisions and advance therapy. Graphical Abstract S. Hettmer and C. Regina discuss the study by Trautmann et al (in this issue of EMBO Molecular Medicine ), which identifies YAP1 positive role in myxoid liposarcomas (MLS) viability and growth, thus highlighting a novel target for therapeutic intervention in MLS.
ISSN:1757-4676
1757-4684
DOI:10.15252/emmm.201910470